Re: Findings of ASCO/ASH 2010

[Guest guest]

I see that ASH 2010 is being held in Orlando, Fl .  Perhaps that should be

where we hold our reunion and let them see the faces of CML. 

________________________________

From: Lottie Duthu <lotajam@...>

CML < >

Sent: Tue, December 15, 2009 12:46:54 AM

Subject: [ ] Findings of ASCO

" According to a duo of " ASCO 2009 presentations, some patients are not being dose

escalated on imatinib prior to switching to dasatinib (Sprycel). Also, switching

to dasatinib was found to be associated with more adverse events than dose

escalation of imatinib. These studies give us a window on real-world clinical

practice and suggest that we need to make greater efforts to educate patients

and providers on how to follow NCCN guidelines,†said the senior author of

both posters, , MD, director of medical oncology at Dana-Farber

Cancer Center and professor of medicine at Harvard Medical School, both in

Boston. "

More on this subject can be found at:

http://tinyurl.com/ydv5u2x

FYI,

Lottie Duthu